Lundbeck's anti-drinking med Selincro nabs final U.K. funding; Endo pays $25 million-plus for testosterone gel Natesto;

> The U.K.'s cost-effectiveness gatekeepers gave their final OK for Lundbeck's anti-alcoholism drug Selincro (nalmefene). Report

> Fingerpaint, a Saratoga Springs, NY-based agency, snapped up a Phoenix-based shop, Olson Communications, in a bid to build out a West Coast presence to attract more pharma clients based there. Report

> Leo Pharma recruited Barbara Osborne to head up its U.S. regional office as president and CEO; she'll also join the Denmark-based company's global executive team. Release

> Endo Pharmaceuticals ($ENDP) snapped up the rights to a testosterone nasal gel, Natesto, from Trimel BioPharma; the drug was approved by the FDA in May. Release

> Novartis ($NVS) regained its online domain name in Indonesia from a local squatter that was using the domain illegally. Report

> Ireland will require pharma companies to disclose payments to doctors and other healthcare professionals beginning Jan. 1; gifts were banned earlier this year. Report

And Finally... Novartis said the FDA has extended its review of the company's new multiple myeloma drug bortezomib. Release

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.